| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoporosis | 20 | 2020 | 230 | 3.570 |
Why?
|
| Malnutrition | 6 | 2020 | 219 | 3.270 |
Why?
|
| Fractures, Bone | 13 | 2018 | 293 | 2.570 |
Why?
|
| Osteoporotic Fractures | 7 | 2020 | 37 | 2.030 |
Why?
|
| Geriatric Assessment | 9 | 2020 | 277 | 1.920 |
Why?
|
| Nutrition Assessment | 5 | 2020 | 170 | 1.660 |
Why?
|
| Bone Density Conservation Agents | 9 | 2019 | 197 | 1.650 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 9 | 2017 | 91 | 1.600 |
Why?
|
| Diphosphonates | 7 | 2016 | 261 | 1.530 |
Why?
|
| Osteoporosis, Postmenopausal | 5 | 2013 | 37 | 1.300 |
Why?
|
| Neoplasms | 18 | 2020 | 15180 | 1.210 |
Why?
|
| Accidental Falls | 7 | 2017 | 142 | 1.120 |
Why?
|
| Femoral Fractures | 3 | 2016 | 56 | 1.090 |
Why?
|
| Bone Density | 13 | 2020 | 467 | 1.030 |
Why?
|
| Hip Fractures | 4 | 2011 | 79 | 0.980 |
Why?
|
| Osteonecrosis | 3 | 2008 | 55 | 0.950 |
Why?
|
| Vitamin D Deficiency | 3 | 2019 | 116 | 0.790 |
Why?
|
| Fractures, Spontaneous | 2 | 2011 | 82 | 0.730 |
Why?
|
| Frailty | 2 | 2019 | 113 | 0.730 |
Why?
|
| Gadolinium | 3 | 2014 | 165 | 0.670 |
Why?
|
| Aged, 80 and over | 28 | 2020 | 29996 | 0.660 |
Why?
|
| Wrist Injuries | 2 | 2010 | 12 | 0.660 |
Why?
|
| Jaw Diseases | 2 | 2008 | 21 | 0.650 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 2 | 2014 | 10 | 0.620 |
Why?
|
| Spinal Fractures | 3 | 2020 | 133 | 0.600 |
Why?
|
| Thiazides | 1 | 2017 | 6 | 0.600 |
Why?
|
| Aged | 40 | 2020 | 70367 | 0.590 |
Why?
|
| Cognitive Dysfunction | 2 | 2019 | 333 | 0.560 |
Why?
|
| Risk Factors | 20 | 2020 | 17622 | 0.560 |
Why?
|
| Dementia | 2 | 2019 | 455 | 0.560 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 561 | 0.540 |
Why?
|
| United States Food and Drug Administration | 8 | 2013 | 333 | 0.530 |
Why?
|
| Product Surveillance, Postmarketing | 5 | 2013 | 42 | 0.530 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2017 | 150 | 0.530 |
Why?
|
| Mass Screening | 2 | 2019 | 1506 | 0.520 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 189 | 0.520 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 257 | 0.510 |
Why?
|
| Pharmacovigilance | 1 | 2014 | 12 | 0.500 |
Why?
|
| Anilides | 1 | 2017 | 267 | 0.500 |
Why?
|
| Postmenopause | 3 | 2018 | 377 | 0.490 |
Why?
|
| Body Mass Index | 2 | 2019 | 2213 | 0.480 |
Why?
|
| Depressive Disorder, Major | 1 | 2019 | 431 | 0.460 |
Why?
|
| Endocrine System | 1 | 2013 | 36 | 0.440 |
Why?
|
| Antineoplastic Agents | 10 | 2019 | 14288 | 0.440 |
Why?
|
| Female | 46 | 2020 | 142293 | 0.440 |
Why?
|
| Dental Care for Chronically Ill | 3 | 2011 | 11 | 0.430 |
Why?
|
| Menopause | 1 | 2013 | 159 | 0.420 |
Why?
|
| Humans | 66 | 2020 | 262248 | 0.400 |
Why?
|
| Contrast Media | 2 | 2014 | 1474 | 0.380 |
Why?
|
| Secondary Prevention | 2 | 2016 | 334 | 0.380 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2011 | 81 | 0.370 |
Why?
|
| Male | 33 | 2020 | 123338 | 0.360 |
Why?
|
| Pyridines | 1 | 2017 | 1243 | 0.360 |
Why?
|
| Jaw | 1 | 2008 | 20 | 0.340 |
Why?
|
| Electronic Health Records | 2 | 2017 | 929 | 0.320 |
Why?
|
| Absorptiometry, Photon | 4 | 2015 | 238 | 0.310 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 5724 | 0.300 |
Why?
|
| Prevalence | 5 | 2020 | 3272 | 0.290 |
Why?
|
| Liver | 1 | 2017 | 2904 | 0.290 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 146 | 0.290 |
Why?
|
| Aging | 5 | 2013 | 1533 | 0.280 |
Why?
|
| Ulna Fractures | 1 | 2006 | 7 | 0.280 |
Why?
|
| Health Education | 1 | 2009 | 309 | 0.280 |
Why?
|
| Radius Fractures | 1 | 2006 | 15 | 0.280 |
Why?
|
| Middle Aged | 26 | 2020 | 86544 | 0.270 |
Why?
|
| Incidence | 7 | 2017 | 5713 | 0.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2014 | 596 | 0.270 |
Why?
|
| Illinois | 3 | 2015 | 24 | 0.270 |
Why?
|
| Retrospective Studies | 11 | 2020 | 38011 | 0.260 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2012 | 1219 | 0.260 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 744 | 0.250 |
Why?
|
| United States | 16 | 2020 | 15574 | 0.240 |
Why?
|
| Weight Loss | 2 | 2019 | 630 | 0.240 |
Why?
|
| Comorbidity | 3 | 2019 | 2397 | 0.220 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 5009 | 0.220 |
Why?
|
| Chicago | 3 | 2009 | 40 | 0.210 |
Why?
|
| Postural Balance | 4 | 2013 | 151 | 0.210 |
Why?
|
| Case-Control Studies | 3 | 2019 | 6104 | 0.200 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 405 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2020 | 2236 | 0.190 |
Why?
|
| Patient Education as Topic | 3 | 2012 | 758 | 0.190 |
Why?
|
| Lumbar Vertebrae | 3 | 2020 | 247 | 0.190 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 4655 | 0.180 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 4563 | 0.180 |
Why?
|
| Women's Health | 2 | 2018 | 206 | 0.180 |
Why?
|
| Orthopedics | 1 | 2020 | 73 | 0.170 |
Why?
|
| Walking Speed | 1 | 2019 | 17 | 0.170 |
Why?
|
| Healthy Lifestyle | 1 | 2019 | 45 | 0.170 |
Why?
|
| Program Development | 3 | 2012 | 264 | 0.170 |
Why?
|
| RANK Ligand | 2 | 2017 | 119 | 0.160 |
Why?
|
| Nutritional Support | 1 | 2019 | 79 | 0.160 |
Why?
|
| Primary Health Care | 1 | 2004 | 790 | 0.160 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 143 | 0.160 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 175 | 0.160 |
Why?
|
| Geriatrics | 1 | 2019 | 97 | 0.160 |
Why?
|
| Focus Groups | 2 | 2012 | 260 | 0.160 |
Why?
|
| Nutritional Status | 1 | 2020 | 338 | 0.160 |
Why?
|
| Drug Approval | 2 | 2009 | 178 | 0.150 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 228 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2020 | 9195 | 0.150 |
Why?
|
| Walking | 2 | 2013 | 277 | 0.150 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2017 | 46 | 0.150 |
Why?
|
| Adult | 14 | 2019 | 78179 | 0.150 |
Why?
|
| Logistic Models | 4 | 2017 | 3450 | 0.150 |
Why?
|
| Cause of Death | 1 | 2020 | 757 | 0.150 |
Why?
|
| Risk Assessment | 7 | 2019 | 6900 | 0.140 |
Why?
|
| Imidazoles | 2 | 2016 | 1003 | 0.140 |
Why?
|
| Prospective Studies | 8 | 2017 | 12923 | 0.140 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 15709 | 0.140 |
Why?
|
| Texas | 2 | 2017 | 6308 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 1901 | 0.130 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2015 | 36 | 0.130 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 1996 | 162 | 0.130 |
Why?
|
| Amyloid | 1 | 1996 | 96 | 0.130 |
Why?
|
| Cancer Survivors | 2 | 2019 | 649 | 0.130 |
Why?
|
| Gray Matter | 1 | 2015 | 63 | 0.130 |
Why?
|
| Meglumine | 1 | 2014 | 19 | 0.130 |
Why?
|
| Biomarkers | 3 | 2019 | 5055 | 0.130 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 105 | 0.130 |
Why?
|
| Kidney Diseases | 2 | 2012 | 692 | 0.120 |
Why?
|
| Hypotension | 1 | 1996 | 209 | 0.120 |
Why?
|
| Hospitals | 1 | 2017 | 491 | 0.120 |
Why?
|
| Heterocyclic Compounds | 1 | 2014 | 119 | 0.120 |
Why?
|
| Gadolinium DTPA | 1 | 2014 | 171 | 0.120 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2017 | 272 | 0.120 |
Why?
|
| Registries | 3 | 2020 | 2188 | 0.120 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 24 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 4976 | 0.120 |
Why?
|
| Calcium | 2 | 2012 | 1545 | 0.110 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 192 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 526 | 0.110 |
Why?
|
| Perimenopause | 1 | 2013 | 3 | 0.110 |
Why?
|
| Drug Information Services | 1 | 2013 | 11 | 0.110 |
Why?
|
| Fracture Healing | 1 | 2013 | 42 | 0.110 |
Why?
|
| Drug Labeling | 1 | 2013 | 29 | 0.110 |
Why?
|
| Hot Flashes | 1 | 2013 | 37 | 0.110 |
Why?
|
| Motor Skills | 1 | 2013 | 103 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 314 | 0.110 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2013 | 110 | 0.110 |
Why?
|
| Age Factors | 6 | 2018 | 5384 | 0.110 |
Why?
|
| Anaphylaxis | 1 | 2013 | 120 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 4323 | 0.100 |
Why?
|
| Bisphosphonate-Associated Osteonecrosis of the Jaw | 1 | 2011 | 13 | 0.100 |
Why?
|
| Amiodarone | 1 | 2012 | 42 | 0.100 |
Why?
|
| Bayes Theorem | 2 | 2013 | 1034 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 6046 | 0.100 |
Why?
|
| Academic Medical Centers | 2 | 2005 | 673 | 0.090 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 205 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 704 | 0.090 |
Why?
|
| Optic Nerve Diseases | 1 | 2012 | 103 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2017 | 9282 | 0.090 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2012 | 225 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2019 | 1424 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 198 | 0.090 |
Why?
|
| Orphan Drug Production | 1 | 2009 | 10 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2011 | 501 | 0.090 |
Why?
|
| Professional Staff Committees | 1 | 2009 | 30 | 0.090 |
Why?
|
| American Dental Association | 1 | 2008 | 1 | 0.080 |
Why?
|
| Precipitating Factors | 1 | 2008 | 6 | 0.080 |
Why?
|
| Tooth Extraction | 1 | 2008 | 11 | 0.080 |
Why?
|
| Dental Care | 1 | 2008 | 15 | 0.080 |
Why?
|
| Physical Therapy Modalities | 1 | 2009 | 96 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 603 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 298 | 0.080 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 305 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1330 | 0.080 |
Why?
|
| Femur Neck | 1 | 2008 | 22 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4337 | 0.080 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2008 | 24 | 0.080 |
Why?
|
| Hip | 1 | 2008 | 28 | 0.080 |
Why?
|
| Hyperthyroidism | 1 | 2008 | 53 | 0.080 |
Why?
|
| Calcitonin | 1 | 2008 | 186 | 0.070 |
Why?
|
| Biomechanical Phenomena | 2 | 2013 | 340 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3983 | 0.070 |
Why?
|
| China | 1 | 2009 | 613 | 0.070 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 1215 | 0.070 |
Why?
|
| Exercise | 2 | 2019 | 1186 | 0.070 |
Why?
|
| Hematinics | 1 | 2008 | 110 | 0.070 |
Why?
|
| Drug Industry | 1 | 2007 | 88 | 0.070 |
Why?
|
| Disease Management | 1 | 2012 | 1063 | 0.070 |
Why?
|
| Self Efficacy | 1 | 2009 | 296 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2008 | 145 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2008 | 203 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 7717 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 4903 | 0.070 |
Why?
|
| Calcaneus | 1 | 2006 | 18 | 0.070 |
Why?
|
| Analgesics | 1 | 2009 | 393 | 0.070 |
Why?
|
| Prognosis | 2 | 2017 | 21737 | 0.070 |
Why?
|
| Algorithms | 1 | 2017 | 3890 | 0.070 |
Why?
|
| Vitamin D | 1 | 2008 | 260 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 1379 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2004 | 1305 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 544 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2009 | 466 | 0.070 |
Why?
|
| Quality of Life | 1 | 2019 | 4582 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 3263 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 928 | 0.060 |
Why?
|
| Survivors | 1 | 2011 | 1035 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1359 | 0.060 |
Why?
|
| Disease Progression | 1 | 2016 | 6693 | 0.060 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 230 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2012 | 854 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2008 | 1554 | 0.060 |
Why?
|
| Health Behavior | 1 | 2009 | 605 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2006 | 244 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 1066 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2011 | 3005 | 0.060 |
Why?
|
| Health Services for the Aged | 1 | 2003 | 50 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 3080 | 0.060 |
Why?
|
| Radiography | 1 | 2008 | 1900 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 948 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2008 | 336 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2005 | 225 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2004 | 255 | 0.050 |
Why?
|
| Hospitalization | 1 | 2012 | 2119 | 0.050 |
Why?
|
| Anemia | 1 | 2008 | 690 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2007 | 676 | 0.050 |
Why?
|
| Health Services Accessibility | 2 | 2007 | 760 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 2152 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 1159 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 10348 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5435 | 0.050 |
Why?
|
| Clinical Trials as Topic | 4 | 2013 | 3755 | 0.050 |
Why?
|
| Perception | 1 | 2002 | 353 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 4745 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2003 | 2804 | 0.040 |
Why?
|
| Melanoma | 1 | 2017 | 5319 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2006 | 1869 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2020 | 188 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2020 | 206 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 33028 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 2420 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 3583 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 14913 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2009 | 447 | 0.040 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 1996 | 16 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 5100 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 203 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 1005 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 1181 | 0.030 |
Why?
|
| Time Factors | 3 | 2019 | 12984 | 0.030 |
Why?
|
| Osteomalacia | 1 | 1994 | 36 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2016 | 203 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6223 | 0.030 |
Why?
|
| Ethics Committees, Research | 1 | 2013 | 40 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 485 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1958 | 0.030 |
Why?
|
| Independent Living | 1 | 2013 | 73 | 0.030 |
Why?
|
| Contraindications | 1 | 2012 | 151 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2013 | 496 | 0.030 |
Why?
|
| Oral Hygiene | 1 | 2011 | 20 | 0.030 |
Why?
|
| Age Distribution | 1 | 2013 | 703 | 0.030 |
Why?
|
| Oral Surgical Procedures | 1 | 2011 | 32 | 0.030 |
Why?
|
| Blindness | 1 | 2012 | 77 | 0.030 |
Why?
|
| Denosumab | 1 | 2011 | 68 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1996 | 1240 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 483 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2011 | 198 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 2156 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1996 | 1466 | 0.020 |
Why?
|
| Glucose | 1 | 1996 | 1247 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2013 | 938 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2011 | 297 | 0.020 |
Why?
|
| Drug Utilization Review | 1 | 2009 | 36 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2009 | 77 | 0.020 |
Why?
|
| Torque | 1 | 2008 | 18 | 0.020 |
Why?
|
| Rotation | 1 | 2008 | 111 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2008 | 26 | 0.020 |
Why?
|
| Fee-for-Service Plans | 1 | 2007 | 40 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 2633 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 305 | 0.020 |
Why?
|
| Peptides | 1 | 2011 | 1476 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 10021 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2009 | 1665 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2007 | 256 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 2063 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2007 | 273 | 0.020 |
Why?
|
| Benzamides | 1 | 2009 | 1834 | 0.010 |
Why?
|
| Risk | 1 | 2008 | 1974 | 0.010 |
Why?
|
| Nurse Practitioners | 1 | 2003 | 63 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 2915 | 0.010 |
Why?
|
| Medicare | 1 | 2007 | 898 | 0.010 |
Why?
|
| Reaction Time | 1 | 2002 | 231 | 0.010 |
Why?
|
| Posture | 1 | 2002 | 216 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2003 | 256 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8882 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 868 | 0.010 |
Why?
|
| Piperazines | 1 | 2009 | 2098 | 0.010 |
Why?
|
| Movement | 1 | 2002 | 557 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 4386 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 899 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2009 | 3538 | 0.010 |
Why?
|
| Heart Failure | 1 | 2009 | 2523 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 12239 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 31239 | 0.010 |
Why?
|
| Child | 1 | 2013 | 29067 | 0.010 |
Why?
|